Reports

Home Depot reported a 6.6% increase in sales to $40.2 billion for Q3 2024. While comparable sales decreased by 1.3%, the company's performance exceeded expectations due to better engagement across seasonal goods and hurricane demand. The company updated its fiscal 2024 guidance.

• Total sales increased by 6.6% to $40.2 billion.
• Comparable sales decreased by 1.3%.

Occidental announced strong Q3 2024 results, with net income of $964 million, or $0.98 per diluted share, and adjusted income of $977 million, or $1.00 per diluted share. The company achieved its highest quarterly operating cash flow this year and made significant progress in debt reduction.

• Operating cash flow reached $3.8 billion.
• Total production exceeded guidance mid-point by 22 Mboed, reaching 1,412 Mboed.

Natera reported a strong third quarter with a 63.9% increase in total revenue to $439.8 million, driven by a 64.4% increase in product revenue. The company also saw improvements in gross margin and processed more tests compared to the same period last year.

• Total revenue increased by 63.9% to $439.8 million compared to Q3 2023.
• Product revenue increased by 64.4% to $436.1 million compared to Q3 2023.

Tyson Foods reported a 1.6% increase in sales for the fourth quarter, reaching $13.565 billion. The company demonstrated significant improvement in profitability, with GAAP operating income increasing by $988 million and adjusted EPS rising by 149%.

• Delivered significant improvement in profitability for the fourth quarter and full year.
• Strengthened financial position with solid cash flow generation.

Rocket Lab reported a strong Q3 2024 with revenue growing 55% year-over-year to $105 million. The company's backlog stands at $1.05 billion, driven by successes across small and medium launch, as well as space systems. They anticipate a strong finish to the year, projecting record revenue for Q4.

• Revenue grew 55% year-on-year to $105 million.
• Backlog reached $1.05 billion, indicating strong demand.

Skyworks' Q4 2024 revenue was $1.025 billion, a 13% sequential increase. GAAP diluted EPS was $0.37, and non-GAAP diluted EPS was $1.55. The company generated annual operating cash flow of $1.825 billion and free cash flow of $1.668 billion.

• Revenue for the fourth fiscal quarter of 2024 was $1.025 billion.
• GAAP diluted earnings per share of $0.37.

CAVA Group reported a strong third quarter with a 39.0% increase in revenue, driven by new restaurant openings and same restaurant sales growth of 18.1%. The company opened 11 net new restaurants, bringing the total to 352. Net income increased to $18.0 million, and the company raised its full-year 2024 guidance.

• CAVA revenue grew by 39.0% year-over-year, reaching $241.5 million.
• Net new CAVA restaurant openings totaled 11, increasing the total restaurant count to 352.

Instacart reported a strong Q3 2024, marked by an 11% year-over-year increase in GTV to $8,303 million and its fourth consecutive quarter of positive GAAP net income. The company's focus on deepening integrations with retailers has proven successful, with integrated retailers experiencing nearly twice the sales growth of non-integrated partners. Instacart is reinvesting in long-term growth opportunities while steadily expanding profitability.

• GTV increased by 11% year-over-year to $8,303 million.
• Orders increased by 10% year-over-year to 72.9 million.

Repligen reported a strong third quarter with a 10% increase in revenue compared to the previous year. The company saw growth in CDMO and equipment sales, as well as record sales in new modalities. Full year revenue guidance was narrowed to $630-$639 million.

• Repligen reported Q3 revenue of $155 million, a 10% increase year-over-year.
• CDMO revenue and orders both increased by approximately 20% year-over-year.

Mosaic reported a net income of $122 million for Q3 2024, with adjusted EPS at $0.34 and adjusted EBITDA at $448 million. The company faced operational interruptions and weather events but managed to recover, with phosphate production returning to full capacity. Clint Freeland is set to retire as CFO, to be succeeded by Luciano Siani Pires.

• Third quarter net income was reported at $122 million, with an Adjusted EBITDA of $448 million.
• Clint Freeland will retire at year-end and will be succeeded by Luciano Siani Pires as CFO.

Roivant reported a net revenue of $4.475 million. The company's R&D expenses were $143.1 million, and G&A expenses were $202.9 million. Roivant reported consolidated cash, cash equivalents and marketable securities of approximately $5.4 billion at September 30, 2024. Roivant continued to return capital through share repurchases with $106M purchased for the quarter.

• Brepocitinib 52-week data from the Phase 2 NEPTUNE study in non-infectious uveitis (NIU) showed potential best-in-indication efficacy sustained to one year.
• IMVT-1402 cleared five Investigational New Drug (IND) applications across a range of therapeutic areas and FDA divisions.

Shift4 reported a strong Q3 2024, marked by record end-to-end payment volume of $43.5 billion, gross revenue less network fees of $365.1 million, and adjusted EBITDA of $187.4 million. The company expanded its adjusted EBITDA margin to 54% excluding recent M&A drag, secured major hospitality wins, and continued its impressive growth with SkyTab installations.

• Shift4 achieved record end-to-end payment volume of $43.5 billion, a 56% increase year-over-year.
• Gross revenue less network fees reached $365.1 million, up 50% compared to Q3 2023.

Light & Wonder reported a 12% increase in consolidated revenue, driven by strong performance across all businesses. The company maintained healthy earnings growth and returned $44 million to shareholders through share repurchases.

• Gaming revenue increased by 15% primarily driven by global Gaming machine sales growth.
• SciPlay revenue grew by 5% driven by the social casino business.

BridgeBio Pharma reported its Q3 2024 financial results, highlighting progress in its late-stage pipeline, including the NDA filing for acoramidis and advancements in other clinical trials. The company ended the quarter with $406 million in cash, cash equivalents, and short-term restricted cash.

• Acoramidis NDA was filed with the U.S. FDA with a PDUFA action date of November 29, 2024.
• CALIBRATE, the Phase 3 clinical trial of encaleret in ADH1, completed screening.

Marathon Digital reported a net loss of $125 million, or $0.42 loss per diluted share, in Q3 2024, compared to a net loss of $390 thousand in the same quarter last year. Revenue increased 35% to $132 million from $98 million in Q3 2023, driven by a higher average price of BTC. The company's BTC holdings increased by 45% to 26,747 BTC, and it secured a $200 million line of credit collateralized by BTC holdings.

• Net loss was $125 million, or $0.42 loss per diluted share, compared to a net loss of $390 thousand in the third quarter of last year.
• Revenue increased 35% to $132 million from $98 million in the third quarter of 2023.

Nuvalent reported third quarter 2024 financial results, highlighting pipeline progress and reiterating key anticipated milestones. The company's cash position is strong at $1.2 billion, expected to extend operating runway into 2028.

• All anticipated 2024 milestones were achieved, reinforcing progress on OnTarget 2026 operating plan.
• Development timelines were accelerated, supporting the goal of achieving the first approved product in 2026.

Rumble Inc. announced record revenues of $25.1 million for Q3 2024, a 39% increase year-over-year, and average MAUs of 67 million, up 26% quarter-over-quarter. The company also highlighted its fourth consecutive quarter of reduced cash usage.

• Revenues increased by $7.1 million to $25.1 million, a 39% increase compared to the same period last year.
• Audience Monetization revenues increased by $5.9 million due to higher advertising and subscription revenue.

Ingram Micro reported a slight decrease in net sales compared to the prior year, but demonstrated an increase in gross margin and income from operations. The company's focus on higher-margin cloud-based solutions and optimization of operating expenses contributed to the improved profitability.

• Net sales totaled $11.8 billion, a 1.4% decrease year-over-year, impacted by lower sales in North America and Latin America, offset by growth in Asia-Pacific.
• Gross margin increased by 2 basis points year-over-year, driven by a shift in sales mix towards higher-margin cloud-based solutions and Other services net sales.

SoundHound AI reported a record third quarter revenue of $25.1 million, an 89% increase year-over-year. The company has expanded into new verticals and diversified its customer base, with significant contributions from automotive, restaurants, financial services, healthcare, and insurance sectors.

• Reported revenue was $25.1 million, up 89% year-over-year.
• Customer concentration improved significantly, with the largest customer contributing only 12% of revenue, compared to 72% in the prior year.

Axsome Therapeutics reported a total net product revenue of $104.8 million for Q3 2024, representing an 81% year-over-year growth. The company is also advancing its pipeline with multiple Phase 3 trial results expected soon and an NDA submission planned.

• Total net product revenue for Q3 2024 was $104.8 million, an 81% increase year-over-year.
• Auvelity net product sales were $80.4 million, representing a 113% year-over-year growth.

American Healthcare REIT reported a GAAP net loss of $(3.1) million and Normalized Funds from Operations attributable to common stockholders (“NFFO”) of $0.36 per diluted share for the three months ended September 30, 2024. Achieved total portfolio Same-Store Net Operating Income (“NOI”) growth of 17.0% for the three months ended September 30, 2024 compared to the same period in 2023.

• Reported GAAP net loss of $(3.1) million and GAAP net loss attributable to common stockholders of $(0.03) per diluted share for the three months ended September 30, 2024.
• Reported Normalized Funds from Operations attributable to common stockholders (“NFFO”) of $0.36 per diluted share for the three months ended September 30, 2024.

ICU Medical announced third quarter 2024 results with revenue of $589.1 million, compared to $553.3 million in the same period last year. GAAP net loss was $(33.0) million, or $(1.35) per diluted share. Adjusted diluted earnings per share was $1.59, compared to $1.57 for the third quarter of 2023. The company updated its fiscal year 2024 guidance for GAAP net loss and adjusted EBITDA.

• Third quarter revenue was $589.1 million, an increase from $553.3 million in the same period last year.
• GAAP gross profit for the third quarter was $204.9 million, compared to $183.9 million in the prior year.

Biohaven reported a net loss of $160.3 million, or $1.70 per share, for the third quarter ended September 30, 2024. The company achieved positive topline results from a pivotal trial with troriluzole in spinocerebellar ataxia (SCA) and initiated a Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine.

• Achieved positive topline results in pivotal study of troriluzole in SCA, demonstrating efficacy on the mean change from baseline in the f-SARA after 3 years of treatment.
• Initiated Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine.

Scholar Rock reported positive topline data from the Phase 3 SAPPHIRE trial of apitegromab in SMA patients and completed enrollment in the Phase 2 EMBRAZE trial for apitegromab in obesity. The company also completed an upsized $345 million public offering. Net loss for the quarter was $64.5 million, or $0.66 per share.

• Reported positive topline data from pivotal Phase 3 SAPPHIRE trial evaluating apitegromab in patients with Spinal Muscular Atrophy (SMA), achieving primary endpoint.
• On track to submit a U.S. Biologics License Application (BLA) and European Union marketing authorisation application (MAA) in 1Q 2025.

Oklo made significant strides in Q3 2024, highlighted by an increase in the customer pipeline to 2,100 Megawatts, driven by new data center clients. The company also achieved key regulatory milestones, including DOE approval for the Fuel Fabrication Facility Design and secured an environmental compliance permit for the Idaho site. Additionally, Oklo began site preparation for its first powerhouse and signed a term sheet to acquire Atomic Alchemy, Inc.

• Expanded customer pipeline to 2,100 MW with addition of two data center customers.
• Received DOE approval for Fuel Fabrication Facility Design, a key step for using recovered nuclear material.

Alight's Q3 2024 revenue reached $555 million. BPaaS revenue grew by 18.6% to $121 million. The company initiated a quarterly dividend program and repurchased $75 million of common stock.

• Revenue decreased slightly by 0.4% to $555 million.
• BPaaS revenue increased by 18.6% to $121 million, representing 21.8% of total revenue.

Paymentus reported a record revenue of $231.6 million, representing a 51.9% year-over-year increase. Net income was $14.4 million, with a GAAP earnings per share of $0.11. Adjusted EBITDA increased by 58.2% year-over-year, reflecting a 30.7% adjusted EBITDA margin.

• Revenue increased by 51.9% year-over-year, reaching a record $231.6 million.
• Gross profit increased by 29.3% year-over-year to $60.7 million.

Crinetics Pharmaceuticals reported its Q3 2024 financial results, highlighting the submission of the NDA for paltusotine and a strengthened balance sheet with a $575 million public offering. The company's focus remains on advancing its pipeline and preparing for the potential launch of paltusotine in 2025.

• Submitted New Drug Application (NDA) for paltusotine for the treatment of acromegaly.
• Strengthened balance sheet with $575 million public offering.

ZoomInfo reported a GAAP revenue of $303.6 million, a decrease of 3% year-over-year. The company's GAAP operating income was $43.5 million, with an adjusted operating income of $111.7 million. They closed the quarter with 1,809 customers with $100,000 or greater in annual contract value, an increase of 12 from the prior quarter.

• GAAP revenue was $303.6 million, a 3% decrease year-over-year.
• GAAP operating income was $43.5 million, and adjusted operating income was $111.7 million.

First Advantage reported revenues of $199.1 million and a net loss of $(8.9) million for the third quarter of 2024. The company's adjusted EBITDA was $64.0 million with a margin of 32.2%. They closed the acquisition of Sterling on October 31, 2024, and are maintaining standalone full-year 2024 guidance while issuing combined company guidance including Sterling.

• Revenues reached $199.1 million.
• Net Loss was $(8.9) million, including $13.2 million of expenses related to the Sterling acquisition.

Sylvamo reported strong Q3 2024 earnings with a 20% adjusted EBITDA margin and outstanding free cash flow, driven by solid operational performance, good commercial execution, and stable input costs. Net income was $95 million, or $2.27 per diluted share, and adjusted EBITDA was $193 million.

• Net income reached $95 million ($2.27 per diluted share) compared to $83 million ($1.98 per diluted share) in the previous quarter.
• Adjusted EBITDA stood at $193 million (20% margin) versus $164 million (18% margin) in the previous quarter.

OUTFRONT Media reported a slight decrease in revenue but an increase in net income for Q3 2024. The company's U.S. Media business showed strength with revenue growth and Adjusted OIBDA growth. A special dividend of $0.75 per share was announced.

• Revenues decreased slightly to $451.9 million.
• Net income attributable to OUTFRONT Media Inc. increased to $34.6 million.

Xenon Pharmaceuticals reported a net loss of $62.8 million for the quarter ended September 30, 2024, compared to a net loss of $48.5 million for the same period in 2023. As of September 30, 2024, cash and cash equivalents and marketable securities were $803.3 million.

• Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025.
• Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES.

Rigetti Computing's total revenues for Q3 2024 were $2.4 million. The company's operating loss was $17.3 million and net loss was $14.8 million. As of September 30, 2024, cash, cash equivalents and available-for-sale securities totaled $92.6 million.

• Total revenues for Q3 2024 were $2.4 million.
• Operating loss for Q3 2024 was $17.3 million.

Zai Lab reported a strong third quarter with a 47% year-over-year increase in net product revenue, driven by VYVGART sales. The company also saw positive results from the China bridging study of KarXT and expects regulatory submissions in early 2025. Additionally, Zai Lab anticipates three product launches in mainland China by the end of 2024.

• Net product revenue increased by 47% year-over-year, reaching $101.8 million.
• VYVGART sales were a primary driver of revenue growth.

Surgery Partners reported a 14.3% increase in revenue to $770.4 million for the third quarter of 2024. Adjusted EBITDA was $128.6 million, representing a 21.9% increase compared to the prior year period. The company reaffirmed its full-year 2024 revenue and Adjusted EBITDA guidance.

• Revenues increased by 14.3% to $770.4 million compared to the prior year period.
• Same-facility revenues increased by 4.2%.

Azenta's Q4 2024 revenue was $170 million, a 1% decrease year-over-year. However, the combined Sample Management Solutions and Multiomics businesses grew 5% organically. The company reported a diluted EPS from continuing operations of ($0.10) and a non-GAAP diluted EPS of $0.18. They are pursuing the sale of B Medical Systems.

• Revenue decreased by 1% year-over-year to $170 million.
• Combined Sample Management Solutions and Multiomics businesses grew 5% organically.

Apogee Therapeutics reported its Q3 2024 financial results, highlighting continued execution across all programs, including positive results from the APG777 Phase 1 trial. The company is on track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024, and interim Phase 1 data for APG990 in 1H 2025. Apogee had $753.8 million in cash, cash equivalents, and marketable securities, providing runway into 2028.

• Reported positive results up to nine months from APG777 Phase 1 trial.
• On track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024 and interim Phase 1 data for APG990 in 1H 2025.

NCR Atleos reported revenue of $1.08 billion, with service revenue reaching a new high of $843 million. GAAP net income was $24 million, and Adjusted EBITDA was $207 million. The company reaffirmed its 2024 guidance, moving Non-GAAP EPS guidance to the high end of the range.

• Revenue of $1.08 billion, with $790 million in recurring revenue.
• GAAP net income of $24 million; Adjusted EBITDA of $207 million.

Mirum Pharmaceuticals reported Q3 2024 global net product sales of $90.3 million, representing an 89% increase compared to Q3 2023. The company increased its 2024 revenue guidance to $330-335 million. Volixibat was granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, and the PDUFA date for chenodiol in CTX is set for December 28, 2024.

• Global net product sales reached $90.3 million, an 89% increase year-over-year.
• LIVMARLI net sales were $59.1 million for the third quarter.

Sunstone Hotel Investors reported a net income of $3.2 million and an adjusted EBITDAre of $53.6 million for Q3 2024. Comparable RevPAR decreased by 1.3%, but when excluding The Confidante Miami Beach and Hilton San Diego Bayfront, RevPAR increased by 2.4%.

• Net income was $3.2 million, down from $15.6 million in the same quarter of the previous year.
• Comparable RevPAR decreased by 1.3% to $207.56.

ImmunityBio reported a net product revenue of approximately $6.0 million during the three months ended September 30, 2024, surpassing net product revenue of $1.0 million in the prior quarter and analyst estimates. The company's cash and marketable securities position was $130.4 million as of September 30, 2024.

• ANKTIVA received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025.
• ANKTIVA is now widely accessible to patients through commercial and government insurance programs, securing coverage for over 200 million medical lives.

ePlus reported a decrease in net sales by 12.3% to $515.2 million, but an increase in consolidated gross profit by 2.5% to $148.0 million. The consolidated gross margin was 28.7%, up from 24.6% in the previous year. Net earnings decreased by 4.1% to $31.3 million, with a diluted EPS of $1.17. Non-GAAP diluted EPS decreased by 2.9% to $1.36.

• Net sales decreased 12.3% to $515.2 million; technology business net sales decreased 13.8% to $493.3 million; service revenues increased 46.0% to $103.7 million.
• Technology business gross billings decreased 5.6% to $808.2 million.

Progyny reported a 2.0% increase in revenue for the third quarter of 2024, reaching $286.6 million. The company added over 80 new clients and secured a leading national health plan and a regional health plan as preferred partners. However, utilization patterns affected revenue and profitability.

• Revenue increased by 2.0% to $286.6 million compared to Q3 2023.
• Over 80 new clients were added, resulting in 1.1 million new covered lives.

EverCommerce reported Q3 2024 revenue of $176.3 million, a 0.9% increase year-over-year, and an adjusted EBITDA of $44.5 million. The company repurchased 1.4 million shares of common stock for approximately $14.6 million during the quarter. Looking ahead to 2025, the focus is on implementing transformation and optimization initiatives.

• Revenue increased by 0.9% to $176.3 million compared to Q3 2023.
• Pro Forma Revenue, excluding fitness, increased 4.3% year-over-year.

Perimeter Solutions reported a significant increase in net sales and adjusted EBITDA for the third quarter of 2024. Net sales increased by 102% to $288.4 million, and adjusted EBITDA increased by 177% to $170.4 million. However, the company experienced a net loss of $89.2 million, or $0.61 loss per diluted share.

• Net sales increased 102% to $288.4 million compared to the prior year quarter.
• Fire Safety sales increased 113% to $251.8 million, while Specialty Products sales increased 50% to $36.6 million.

Wave Life Sciences reported positive clinical updates across DMD and AATD, achieved first-ever RNA editing in humans, and advanced its pipeline. The company's cash runway is expected into 2027.

• Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 in alpha-1 antitrypsin deficiency.
• WVE-007 clinical trial on track for 1Q 2025, with preclinical data supporting monotherapy or synergistic use with GLP-1s.

Rocket Companies reported a mixed Q3 2024 with a GAAP net loss of $481 million but an adjusted net income of $166 million. The company saw a 32% year-over-year increase in adjusted revenue and the highest adjusted EBITDA in two years, driven by growth in purchase and refinance market share.

• Total revenue was $647 million, and adjusted revenue reached $1.323 billion, exceeding guidance.
• GAAP net loss was $481 million, or $0.19 loss per diluted share, while adjusted net income was $166 million, or $0.08 adjusted diluted earnings per share.

Perdoceo Education Corporation reported a 5.6% decrease in revenue for the third quarter of 2024, amounting to $169.8 million. However, operating income increased by 4.0% to $44.8 million. Total student enrollments increased by 11.0%, with CTU increasing by 13.6% and AIUS by 4.0%.

• Total student enrollments increased by 11.0% due to gains at CTU and AIUS.
• Operating income increased 4.0% to $44.8 million.

TreeHouse Foods reported mixed Q3 2024 results with net sales of $839.1 million, impacted by a voluntary griddle product recall. However, supply chain savings initiatives led to margin improvement, with adjusted EBITDA within the company's guidance range.

• Net sales were $839.1 million; adjusted net sales, excluding the product recall, were $854.4 million.
• Net loss from continuing operations was $(3.4) million.

Schrödinger reported a decrease in total revenue for the third quarter of 2024, while software revenue increased. The company announced a multi-target research and licensing collaboration with Novartis, receiving $150 million upfront. Updated financial guidance for 2024 was provided, with increased confidence in software revenue growth.

• Total revenue for the third quarter was $35.3 million, a decrease from $42.6 million in the third quarter of 2023.
• Software revenue for the third quarter increased 10% to $31.9 million, compared to $28.9 million in the third quarter of 2023.

TeraWulf reported a revenue increase of 42.8% year-over-year, reaching $27.1 million for Q3 2024. The company's operational self-mining capacity grew by 100% to 10.0 EH/s. Strategic activities post-Q3 included the sale of Nautilus JV interest, a new Lake Mariner ground lease, a convertible note offering, and a share buyback program.

• Revenue increased to $27.1 million in Q3 2024, a 42.8% increase compared to Q3 2023.
• Cost of revenue (exclusive of depreciation) increased to $14.7 million in Q3 2024.

IAS reported an 11% increase in total revenue to $133.5 million for Q3 2024. Net income was $16.1 million, representing a 12% margin, and adjusted EBITDA increased to $50.6 million, resulting in a 38% margin.

• Total revenue increased by 11% year-over-year to $133.5 million.
• Net income reached $16.1 million, with a 12% margin.

Disc Medicine reported a net loss of $26.6 million for the third quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $487.4 million as of September 30, 2024. They also completed a $200 million non-dilutive debt financing in November 2024.

• Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), aligning on study parameters and potential for accelerated approval.
• Presented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at ASN Kidney Week 2024.

NW Natural Holdings reported a net loss of $27.2 million ($0.71 per share) for the third quarter of 2024, compared to a net loss of $23.7 million ($0.65 per share) for the same period in 2023. The company reaffirmed its 2024 EPS guidance in the range of $1.94 to $2.14 on a GAAP basis or $2.20 to $2.40 on a non-GAAP Adjusted Basis, and long-term EPS growth rate target of 4% to 6% from 2022 through 2027.

• Reported a net loss of $27.2 million ($0.71 per share) for the third quarter of 2024, compared to a net loss of $23.7 million ($0.65 per share) for the same period in 2023.
• Added nearly 17,000 gas and water utility connections in the last 12 months for a combined growth rate of 1.9% as of September 30, 2024, mainly driven by strong water acquisitions.

Viridian Therapeutics reported positive topline phase 3 data for veligrotug and initiated two global phase 3 clinical trials of subcutaneous VRDN-003. The company's cash runway extends into the second half of 2027, supported by net proceeds of $243.2 million from a public offering.

• Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED).
• Initiated two global phase 3 clinical trials of subcutaneous VRDN-003, REVEAL-1 and REVEAL-2 in August, in active and chronic TED, respectively.

Novavax reported total revenue of $85 million for Q3 2024, with product sales contributing $38 million and licensing, royalties, and other revenue at $46 million. The company ended the quarter with $1 billion in cash and receivables and is advancing its R&D strategy beyond COVID-19 and influenza.

• Achieved total revenue of $85 million in the third quarter of 2024.
• Ended the third quarter of 2024 with $1 billion in cash and receivables.

Topgolf Callaway Brands announced Q3 2024 results that exceeded expectations, driven by strong venue profitability at Topgolf and Callaway's leading position in golf clubs and balls. The company reaffirmed its expectation for full year positive Adjusted Free Cash Flow for the total Company and Topgolf.

• Q3 Consolidated Revenues and Adjusted EBITDA were ahead of expectations.
• The Callaway brand maintained its #1 position in U.S. market share in total golf clubs and achieved record U.S. market share in golf ball.

Triumph Group reported a net sales of $287.5 million with a 1% growth and an operating income of $32.4 million. The company's adjusted EBITDAP stood at $42.6 million. Due to the strong aftermarket demand and the interiors improvements, Triumph raised its fiscal 2025 earnings and cash flow guidance.

• Net sales of $287.5 million, a 1% year-over-year increase.
• Operating income of $32.4 million with an 11% operating margin.

Dyne Therapeutics reported positive progress in their ACHIEVE and DELIVER trials, with IND clearance for DYNE-101. The company is enrolling a registrational cohort of DYNE-251 DELIVER trial in DMD and anticipates reporting new data from the ACHIEVE trial in early January 2025. The company's cash position is expected to fund operations into the second half of 2026.

• FDA cleared the IND application for DYNE-101 for DM1.
• New clinical data from DYNE-101 ACHIEVE trial is expected in early January 2025.

BioLife Solutions reported a 30% increase in total revenue to $30.6 million, driven by a 43% increase in Cell Processing revenue. The company increased its Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million and total 2024 revenue guidance to $98.0 million to $100.0 million, reflecting the impact of the SciSafe divestiture.

• Cell Processing revenue grew 6% sequentially to $19.0 million, a 43% increase compared to 2023.
• GAAP gross margin was 51%, and non-GAAP adjusted gross margin was 54%.

Smith Douglas Homes Corp. announced record third-quarter results for 2024, with significant increases in home closings, home closing revenue, and active community count. The company's strategic growth into new geographic areas and commitment to operational efficiency contributed to pretax income of $39.6 million.

• Home closings increased by 39% to 812.
• Home closing revenue increased by 41% to $277.8 million.

Cannae Holdings released its third quarter 2024 financial results, which are included in its Letter to Shareholders.

• Third quarter 2024 financial results were released.
• Results are available on the Cannae website.

Dave Inc. reported a record third quarter with revenue up 41% year-over-year to $92.5 million and net income of $0.5 million, a $12.5 million increase year-over-year. The company also raised its full-year 2024 revenue and Adjusted EBITDA guidance.

• Revenue increased by 41% year-over-year to $92.5 million, marking the fourth consecutive quarter of accelerating revenue growth.
• Net income increased by $12.5 million year-over-year to $0.5 million.

Replimune Group, Inc. announced financial results for the fiscal second quarter ended September 30, 2024. The company believes that existing cash, cash equivalents and short-term investments, as of September 30, 2024 will enable the Company to fund operations into the second half of 2026.

• Rapid progress towards BLA submission for RP1.
• IGNYTE data presented at major medical meetings, well-received by the oncology community.

Target Hospitality reported revenue of $95.2 million and net income of $20.1 million for the three months ended September 30, 2024. The company's strong cash generation and financial flexibility position it well for future growth opportunities.

• Revenue reached $95.2 million.
• Net income was $20.1 million.

Cogent Biosciences reported its Q3 2024 financial results, highlighting the completion of enrollment in the Phase 3 PEAK trial, acceleration of enrollment in the SUMMIT trial, and initiation of a Phase 1 trial for the FGFR2 inhibitor, CGT-4859. The company's cash position is strong at $346 million, expected to fund operations into late 2026.

• Completed enrollment in PEAK, a Phase 3 trial for GIST patients.
• Accelerated enrollment in SUMMIT, a registration-directed trial for NonAdvSM.

GRAIL reported a 38% increase in total revenue to $28.7 million, with Galleri revenue growing by 52% to $25.4 million. The company's net loss was $125.7 million, while adjusted EBITDA showed an improvement. Over 250,000 Galleri tests have been sold since launch, and the company is focusing on cost management and advancing registrational studies.

• Total revenue increased by 38% year-over-year to $28.7 million.
• Galleri revenue grew by 52% year-over-year to $25.4 million.

Prothena reported a net loss of $59.0 million for the third quarter of 2024, compared to a net income of $21.9 million for the same period in 2023. Total revenue for the third quarter of 2024 was $1.0 million, primarily from collaboration revenue from Bristol Myers Squibb.

• Net loss for the third quarter of 2024 was $59.0 million, compared to a net income of $21.9 million for the third quarter of 2023.
• Total revenue for the third quarter of 2024 was $1.0 million, primarily from collaboration revenue from Bristol Myers Squibb.

ORIC Pharmaceuticals reported cash and investments of $282.4 million, expected to fund the operating plan into late 2026. The company continues to advance ORIC-114 and ORIC-944 programs towards registrational studies. Clinical collaborations were announced to support the ORIC-944 trial in combination with AR inhibitors for prostate cancer.

• Presented preclinical data supporting ORIC-114's potential as a best-in-class treatment for EGFR exon 20 insertions and other atypical mutations.
• Announced clinical collaborations to support the trial evaluating ORIC-944 in combination with AR inhibitors for prostate cancer.

Shoals Technologies Group reported a revenue decrease of 24% to $102.2 million compared to the prior-year period. The company experienced a net loss of $0.3 million, but adjusted EBITDA decreased to $24.5 million. Despite challenges, Shoals raised the midpoint of its full-year revenue outlook.

• Revenue decreased by 24% year-over-year to $102.2 million due to project delays.
• Gross profit increased to $25.4 million, with a gross profit percentage of 24.8%.

PubMatic announced strong Q3 2024 results, exceeding expectations with revenue of $71.8 million, a 13% increase year-over-year. The company saw significant growth in omnichannel video, up 25%, and reported a gross profit of $46.3 million, up 23% year-over-year. Despite a net loss of $(0.9) million, adjusted EBITDA reached $18.5 million. The company actively repurchased 3.6 million shares year-to-date, demonstrating a commitment to shareholder value.

• Revenue reached $71.8 million, a 13% increase compared to Q3 2023.
• Omnichannel video revenue grew by 25% year-over-year.

Cronos Group reported a 38% increase in net revenue for Q3 2024, reaching $34.3 million. The company's Spinach® brand became the top-selling cannabis brand in Canada, and Cronos maintains a strong balance sheet with $862 million in cash and cash equivalents. The consolidation of Cronos Growing Company has strengthened the supply chain, which is anticipated to lead to improved margins.

• Net revenue in Q3 2024 increased by 38% year-over-year to $34.3 million.
• Spinach® became the number one cannabis brand in Canada.

Avadel Pharmaceuticals reported $50.0 million in net product revenue for the third quarter 2024, driven by sales of LUMRYZ. The company also received FDA approval for LUMRYZ for pediatric narcolepsy and saw a court uphold the FDA's determination that LUMRYZ is clinically superior to twice-nightly oxybate products. They had 2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter.

• Generated $50.0 million in net revenue from sales of LUMRYZ™.
• Had 2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter.

Pagaya Technologies Ltd. reported strong Q3 2024 results, achieving record total revenue of $257 million, a GAAP operating income of $22 million, and an adjusted EBITDA of $56 million. The company focused on profitable, sustainable growth and is progressing towards GAAP profitability and cash flow generation in 2025.

• Network volume grew by 11% year-over-year, reaching $2.4 billion.
• Total revenue increased by 21% year-over-year to $257 million, driven by a 24% increase in revenue from fees.

SI-BONE reported a strong Q3 2024 with worldwide revenue of $40.3 million, representing a growth of approximately 19%. The company significantly improved its financial performance, reducing its net loss by approximately 34% and its Adjusted EBITDA loss by approximately 94%. They expect to achieve positive Adjusted EBITDA in the fourth quarter of 2024.

• Worldwide revenue reached $40.3 million, a growth of approximately 19%.
• U.S. revenue was $38.3 million, representing growth of approximately 18%.

Repay Holdings Corporation reported a 6% increase in revenue and a 9% increase in gross profit for Q3 2024. The company's free cash flow increased by 250% year-over-year. REPAY updated its reported Free Cash Flow Conversion target from approximately 60% to approximately 65%.

• 9% year-over-year gross profit growth in Q3
• Consumer Payments gross profit growth of approximately 2% year-over-year

Ginkgo Bioworks reported a 61% increase in total revenue to $89 million for Q3 2024, which includes $45 million from a non-cash deferred revenue release. Excluding this impact, revenue decreased by 21%. The company signed new deals with Novo Nordisk and achieved a major research milestone with Merck. They also made progress on cost reductions and are consolidating their real estate footprint.

• Total revenue increased to $89 million, up 61% year-over-year, including a $45 million non-cash deferred revenue release.
• Cell Engineering revenue, excluding the deferred revenue release, was $30 million, a 20% decrease year-over-year.

Microvast reported a strong Q3 2024 with record revenue, a significant increase in gross margin, and a shift to net profit compared to the previous year. The company also saw improvements in operating expenses and adjusted EBITDA.

• Revenue increased by 26.6% year-over-year to $101.4 million.
• Gross margin improved from 22.3% to 33.2%.

Legacy Housing Corporation reported its financial results for the third quarter ended September 30, 2024. The company hosted a record number of customers at its 2024 Fall Show and saw orders written at the show push their backlog into the first quarter of 2025.

• Legacy hosted a record number of customers at its 2024 Fall Show in late September.
• Updated interior and exterior finishes were showcased to match the preferences of younger homebuyers.

Net Power made steady progress on commercializing its clean, firm power solution, completing major plant upgrades for Baker Hughes' equipment validation program at their La Porte, Texas demonstration plant and advancing their first utility-scale plant deployment, Project Permian, which is on schedule.

• Commissioning first phase of Baker Hughes equipment validation at La Porte demonstration facility.
• Advanced Front-End Engineering and Design (FEED) work for Project Permian, the Company’s first utility-scale project in West Texas; FEED on track to conclude in Q4 2024.

The Honest Company reported strong Q3 2024 results, achieving record revenue of $99 million, a 15% increase year-over-year. The company delivered positive net income and expanded gross margin by 710 basis points to 38.7%. Due to this performance, the company raised its full year 2024 revenue and adjusted EBITDA outlook.

• Revenue increased by 15% to $99 million, driven by strong performance in baby products and wipes.
• Gross margin expanded by 710 basis points to 38.7% due to improvements in supply chain, product costs, and trade spend.

Crescent Capital BDC reported a net investment income of $0.64 per share and a net income of $0.41 per share for the quarter ended September 30, 2024. The company's net asset value per share was $20.20 as of the same date. A fourth quarter regular cash dividend of $0.42 per share and a third quarter supplemental cash dividend of $0.07 per share were declared.

• Net investment income was $0.64 per share for Q3 2024.
• Net income was $0.41 per share for Q3 2024.

Hertz Global Holdings reported a third quarter revenue of $2.6 billion. The company experienced a GAAP net loss of $1.3 billion, which included a non-cash asset impairment charge of $1.0 billion, and an adjusted net loss of $208 million. Corporate liquidity stood at $1.6 billion at the end of the quarter.

• Revenue reached $2.6 billion.
• GAAP net loss was $1.3 billion, including a $1.0 billion non-cash asset impairment charge.

Autolus Therapeutics reported a net loss of $82.1 million for the third quarter ended September 30, 2024. The FDA approved AUCATZYL, triggering a $30 million milestone payment from Blackstone. The company's cash and cash equivalents totaled $657.1 million.

• AUCATZYL (obecabtagene autoleucel) was approved by the US FDA on November 8, 2024.
• BLA approval triggered a $30 million milestone payment to Autolus from Blackstone.

Montauk Renewables announced strong third-quarter results, with an 18.4% increase in revenues to $65.9 million and a 31.8% increase in net income to $17.0 million compared to the third quarter of 2023. The company's RNG production remained flat at 1.4 million MMBtu, while RINs sold increased by 14.5%.

• RINs sold increased by 14.5% compared to Q3 2023, reaching 15.8 million.
• Revenues increased by 18.4% to $65.9 million compared to Q3 2023.

Kodak reported third-quarter 2024 financial results, featuring a decrease in revenue to $261 million but a significant increase in net income to $18 million. The company focused on strategic investments in growth areas like Advanced Materials & Chemicals and addressed industry dynamics through tariff initiatives.

• Consolidated revenues reached $261 million, a 3% decrease compared to Q3 2023.
• Gross profit totaled $45 million, reflecting a 10% decrease from the previous year.

Erasca reported positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort, bolstering conviction in the ongoing SEACRAFT-2 registrational trial. The company's RAS targeting franchise is on track with planned IND submissions, and a robust balance sheet with $463 million in cash is expected to fund operations into H1 2027.

• Positive preliminary Phase 1b data from SEACRAFT-1 refined clinical development focus on NRASm melanoma.
• SEACRAFT-2 registrational trial targeting NRASm melanoma has potential for approval based on high unmet need.

Ambac Financial Group reported a net loss of $(28) million for the third quarter of 2024, or $(0.63) per diluted share. However, the company experienced significant growth in its P&C premium production, which increased by 86% year-over-year, and a 64% increase in insurance distribution revenue. The Specialty P&C Insurance segment also showed improvement with a better combined ratio.

• Net loss of $(28) million or $(0.63) per diluted share; Adjusted net loss of $(19) million or $(0.46) per diluted share
• Total P&C Premium Production increased 86% from Q3 2023, reaching $260 million.

Rackspace Technology reported a revenue of $676 million for Q3 2024, an 8% decrease compared to Q3 2023. The company's Q3 results exceeded the midpoint of its guidance for revenue, operating profit, and EPS.

• Revenue was $676 million, down 8% year-over-year.
• Private Cloud revenue was $258 million, down 14% year-over-year.

Altimmune reported a net loss of $22.8 million, or $0.32 net loss per share, for the third quarter ended September 30, 2024. The company's cash, cash equivalents and short-term investments totaled $139.4 million as of September 30, 2024. Enrollment was completed in the Phase 2b IMPACT trial of pemvidutide in MASH, with top-line efficacy data expected in Q2 2025.

• Completed enrollment in Phase 2b IMPACT trial of pemvidutide in MASH; top-line efficacy data expected in Q2 2025.
• Successfully completed obesity End-of-Phase 2 meeting with the FDA, reaching agreement on Phase 3 clinical trials.

Theravance Biopharma reported financial and operational results for the third quarter of 2024, highlighting strong YUPELRI demand and progress on the CYPRESS study. The company also announced the formation of a Strategic Review Committee to assess alternatives to unlock shareholder value.

• Achieved a strong quarter for YUPELRI demand through collaboration with Viatris.
• Quarterly net sales reached an all-time high.

Organogenesis Holdings Inc. reported a net revenue of $115.2 million for Q3 2024, a 6% increase compared to Q3 2023. Net income increased by $9.1 million to $12.3 million. The company updated its revenue guidance for the year ending December 31, 2024, expecting net revenue between $455.0 million and $480.0 million.

• Net revenue for Q3 2024 was $115.2 million, up 6% year-over-year.
• Advanced Wound Care products revenue increased by 7% compared to Q3 2023.

Hudson Pacific Properties reported a total revenue of $200.4 million and a net loss attributable to common stockholders of $97.9 million, or $0.69 per diluted share, for the third quarter of 2024. The company signed 539,000 sq ft of office leases in 3Q and 1.6 million sq ft year to date.

• Total revenue was $200.4 million, compared to $231.4 million in the same quarter of the previous year, due to the sale of One Westside and expiration of the Block lease at 1455 Market.
• Net loss attributable to common stockholders was $97.9 million, or $0.69 per diluted share, compared to a net loss of $37.6 million, or $0.27 per diluted share, in the same quarter of the previous year, primarily due to non-cash impairments associated with potential asset sales.

EVgo reported record third-quarter revenue of $67.5 million, a 92% increase year-over-year, driven by growth in charging network and eXtend revenues. Network throughput reached 78 GWh, up 111% year-over-year. The company added over 270 new operational stalls and 147,000 new customer accounts, reaching more than 1.2 million overall.

• Record revenue of $67.5 million, representing a 92% increase year-over-year.
• Charging network revenue totaled $43.1 million, a 98% increase year-over-year.

Eton Pharmaceuticals reported a strong third quarter with product sales reaching $9.8 million, a 40% increase year-over-year. The company achieved positive GAAP net income from product revenue for the first time. They also entered an agreement to acquire Increlex and had their NDA for ET-400 accepted by the FDA.

• Delivered 15th straight quarter of sequential growth in product sales and reported positive GAAP net income.
• Eton reported third quarter 2024 product sales of $9.8 million, representing 40% growth over the prior year period.

Absci reported revenue of $1.7 million for Q3 2024, driven by partnered programs. The company continues to advance its internal pipeline programs and expects to advance at least one additional internal asset program to a lead stage this year. They also anticipate signing drug creation partnerships with at least four partners in 2024. Net loss was $27.4 million for the quarter, and cash, cash equivalents, and short-term investments totaled $127.1 million as of September 30, 2024.

• Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling the first milestone under their collaboration.
• Entered into a collaboration with Twist Bioscience to design a novel therapeutic using AI.

Zevra Therapeutics reported a net revenue of $3.7 million for Q3 2024, driven by reimbursements from the French expanded access program for arimoclomol and royalties from the AZSTARYS® license agreement. The company's cash, cash equivalents, and investments totaled $95.5 million. The FDA approval of MIPLYFFA capsules for NPC treatment was a major milestone.

• FDA approved MIPLYFFA capsules for the treatment of Niemann-Pick disease type C (NPC).
• As of Oct. 31, Zevra received 90 prescription enrollment forms for MIPLYFFA, with 30% approved for reimbursement.

Runway Growth Finance Corp. announced its Q3 2024 financial results, reporting a total investment income of $36.7 million and a net investment income of $15.9 million, or $0.41 per share. The investment portfolio totaled $1.1 billion. The company also declared a fourth quarter 2024 regular dividend of $0.40 per share.

• Total investment income was $36.7 million.
• Net investment income was $15.9 million, or $0.41 per share.

NeuroPace reported a 28% year-over-year increase in revenue to $21.1 million in Q3 2024. The company also demonstrated operating discipline by decreasing cash burn. Increased full-year 2024 revenue guidance to $78 million to $80 million.

• Reported record revenue of $21.1 million in Q3 2024, a 28% increase compared to Q3 2023.
• Achieved a strong gross margin of 73.2%.

Olema Oncology reported a net loss of $34.6 million for the third quarter of 2024, with cash, cash equivalents, and marketable securities totaling $214.8 million as of September 30, 2024. The company is advancing its clinical programs for palazestrant and OP-3136, with key milestones expected in the near term.

• Presented new preclinical data for OP-3136 demonstrating anti-tumor activity and enhanced activity of palazestrant combinations.
• New clinical data for palazestrant in combination with ribociclib to be presented at SABCS in December.

Acacia Research Corporation reported a significant increase in consolidated revenue, up 131% year-over-year, driven by strong performance in its energy and industrial operations. However, the company recorded a net loss for the quarter, while also generating positive Adjusted EBITDA and making a strategic acquisition post-quarter.

• Consolidated revenue increased by 131% year-over-year to $23.3 million.
• GAAP net loss was $14.0 million, or $0.14 diluted net loss per share.

GrafTech International Ltd. reported a net sales of $131 million and a net loss of $36 million, or $0.14 per share for Q3 2024. The company exceeded cost reduction goals and generated positive cash flow through working capital and capital expenditure management. They also grew sales volume 9% year-over-year.

• Exceeded cost reduction goals resulting in significant cost improvement.
• Generated positive cash flow through working capital and capital expenditure management.

Groupon's Q3 2024 results showed a mixed performance with revenue at $114.5 million, a 9% decrease year-over-year, while achieving a net income of $14.5 million and an adjusted EBITDA of $14.8 million. The company exited the quarter with $159.7 million in cash.

• Global revenue was $114.5 million, a decrease of 9% year-over-year.
• Global billings totaled $373.4 million.

OmniAb reported a decrease in revenue for Q3 2024, primarily due to the timing of milestones and lower ion channel service revenue. Despite the revenue decline, research and development and general and administrative expenses decreased. The company maintains a strong cash position and is focused on sustainable, profitable growth.

• Revenue for the third quarter of 2024 was $4.2 million, compared to $5.5 million for the same period in 2023.
• Net loss for the third quarter of 2024 was $16.4 million, or $0.16 per share, compared to a net loss of $15.7 million, or $0.16 per share, for the same period in 2023.

Hallador Energy Company reported a positive financial turnaround in Q3 2024, with total revenue increasing to $105.0 million and net income reaching $1.6 million, or $0.04 earnings per share. The company signed a non-binding term sheet with a data center developer and focused on strengthening its balance sheet through debt reduction.

• Total revenue increased by 12% to $105 million, driven by a 21% increase in electric sales.
• Net income increased to $1.6 million, a significant improvement from the previous quarter's loss.

Quantum-Si reported revenue of $787,000 for the third quarter of 2024. The company is focusing on commercial execution and innovation, with new kits on track for launch in Q4. They anticipate not achieving their full year guided revenue range of $3.7 million to $4.2 million.

• Reported revenue of $787,000 for the third quarter of 2024.
• Liberate Bio integrated Platinum® Next-Generation Sequencing into their platform.

Aura Biosciences reported positive Phase 2 end-of-study data with Bel-sar in early-stage choroidal melanoma and the ongoing Phase 3 CoMpass trial recently received authorization to start enrolling patients in Europe. Multiple clinical complete responses were observed with a single low dose of Bel-sar in the ongoing Phase 1 trial in non-muscle invasive bladder cancer. The company's strong cash position is expected to support operations into 2H 2026.

• Presented positive Phase 2 end of study data with Bel-sar in early-stage choroidal melanoma.
• Received authorization to start enrolling patients in Europe in the ongoing Phase 3 CoMpass trial.

Prime Medicine reported a net loss of $52.5 million for the third quarter of 2024. They received $110 million upfront from Bristol Myers Squibb through a strategic research collaboration. Pro-forma cash, cash equivalents, and investments are expected to fund operations into 1H 2026.

• Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT.
• Initiated IND-enabling activities for Wilson’s Disease program in 4Q 2024, on track to file IND and/or CTA in 1H 2026.

Terns Pharmaceuticals reported its Q3 2024 financial results, highlighting positive topline results from the Phase 1 study of TERN-601 and a successful equity raise of $172.7 million that extends the company's cash runway into 2028. The company's cash, cash equivalents, and marketable securities totaled $372.8 million as of September 30, 2024.

• TERN-601 demonstrated class-leading potential as a differentiated, once-daily, oral GLP-1R agonist for obesity.
• Interim data from the Phase 1 CARDINAL trial of TERN-701 is expected in early December 2024.

Quanterix announced preliminary financial results for Q3 2024, achieving its sixth consecutive quarter of double-digit growth with a revenue of $35.7 million, a 13% increase compared to the prior year, and reaffirmed its full year 2024 revenue guidance of $134 million to $138 million. The company also disclosed the need to restate certain prior period financial statements.

• Revenue of $35.7 million, a 13% increase compared to the corresponding prior year period.
• GAAP gross margin of 58.9% and Non-GAAP gross margin of 53.4%.

Pangaea Logistics Solutions reported a net income of $5.1 million, or $0.11 per diluted share, and an adjusted net income of $11.1 million, or $0.24 per diluted share, on total revenue of $153.1 million for the third quarter of 2024. The company's TCE rates exceeded the average Baltic Panamax and Supramax indices by 19%.

• Net income attributable to Pangaea was $5.1 million, or $0.11 per diluted share.
• Adjusted net income attributable to Pangaea was $11.1 million, or $0.24 per diluted share.

Korro Bio reported its third quarter 2024 financial results, highlighting a regulatory filing submission, the formation of a Clinical Advisory Board, and a collaboration agreement with Novo Nordisk. The company ended the quarter with $169.1 million in cash, cash equivalents, and marketable securities, expecting this to fund operations into the second half of 2026.

• Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD).
• Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team.

Radiant Logistics reported revenues of $203.6 million and net income of $3.4 million, or $0.07 per share, for the first fiscal quarter ended September 30, 2024. The company also reported adjusted EBITDA of $9.5 million.

• Revenues decreased by 3.4% to $203.6 million compared to the prior year.
• Gross profit decreased by 5.9% to $54.1 million compared to the prior year.

Corvus Pharmaceuticals reported a net loss of $40.2 million for the third quarter ended September 30, 2024, compared to a net loss of $6.0 million for the same period in 2023. As of September 30, 2024, Corvus had cash, cash equivalents and marketable securities of $41.7 million compared to $27.1 million as of December 31, 2023. The company expects its cash to fund operations into 2026.

• Phase 1 clinical trial of Soquelitinib in Atopic Dermatitis is enrolling patients in the second dosing cohort, with interim data expected in December 2024.
• The registration Phase 3 clinical trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) is enrolling with multiple clinical sites open.

Viant Technology Inc. reported strong third-quarter results, with revenue, contribution ex-TAC, and adjusted EBITDA exceeding expectations. Advertiser spending hit a new record, driven by CTV spending and the introduction of ViantAI.

• Total advertiser spend on the platform reached a record high, with unprecedented CTV spend.
• CTV spend grew nearly 50% year-over-year, boosted by the Direct Access program and Household ID technology.

Sanara MedTech reported a 35% increase in net revenue to $21.7 million for Q3 2024, marking the twelfth consecutive record net revenue quarter. However, the company experienced a net loss of $2.9 million, primarily due to increased SG&A costs related to the Tissue Health Plus (THP) platform buildout, higher interest expense, and an increase in expense due to change in fair value of earnout liabilities.

• Net revenue increased by 35% year-over-year to $21.7 million, marking the twelfth consecutive record revenue quarter.
• The number of facilities selling Sanara's products increased to over 900 in Q3 2024, compared to over 600 in Q3 2023.

Voyager Therapeutics reported increased collaboration revenue and a reduced net loss for the third quarter of 2024. The company's cash position remains strong, providing a runway into 2027.

• Licensed TRACER™ capsid to Novartis in 5th partnered program, receiving $15 million upfront.
• Achieved 3rd development candidate in partnership with Neurocrine, triggering a $3 million milestone payment.

Blade Air Mobility reported a 4.8% increase in revenue to $74.9 million, driven by growth in the Medical and Short Distance segments. The company achieved positive Passenger Segment Adjusted EBITDA on a trailing twelve-month basis, ahead of schedule. They also announced a strategic alliance with OrganOx to enhance organ transplant logistics.

• Operating Cash Flow increased by $4.3 million to $6.4 million.
• Free Cash Flow, Before Aircraft Acquisitions, increased by $2.4 million to $3.7 million.

Kopin Corporation reported a 26% increase in revenue for Q3 2024, reaching $13.3 million. The growth was primarily driven by a surge in defense product revenues, which increased by 109% year-over-year. The company is focused on application-specific optical solutions, particularly in the defense sector, and anticipates achieving double-digit revenue growth for 2024.

• Revenue for Q3 2024 reached $13.3 million, a 26% increase year-over-year.
• Defense product revenues increased by 109% year-over-year.

Heron Therapeutics announced its Q3 2024 financial results, reporting positive Adjusted EBITDA and continued revenue growth. The company is narrowing its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA. Key developments include the approval and upcoming launch of the ZYNRELEF VAN and the inclusion of ZYNRELEF in the CMS Final Rule Non-Opioid Policy for Pain Relief.

• Reported positive YTD 2024 Adjusted EBITDA of $1.4 million.
• Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million.

EVI Industries reported record first quarter results with achievements in revenue, gross profit, operating profit, and net income. The company also completed one acquisition and invested in long-term growth and efficiency initiatives.

• Revenue increased by 6% compared to the same period last year.
• Gross profit increased by 12% to a record $29 million, with gross margin increasing to a record 30.8%.

Alta Equipment Group reported a decrease in total revenues to $448.8 million, impacted by uncertainty in end-user markets and a $14.0 million discrete tax expense. Despite challenges in equipment sales, the product support business performed well, and the company reduced net debt by $38.7 million. The Board of Directors approved an increase to the share buyback authorization from $12.5 million to $20.0 million.

• Total revenues decreased to $448.8 million year over year.
• Construction Equipment and Material Handling revenues were $262.3 million and $168.9 million, respectively.

Sangamo Therapeutics reported a net income of $10.7 million for Q3 2024, a significant turnaround from the $104.2 million net loss in Q3 2023. Revenues increased substantially due to the Genentech collaboration. The company also announced a clear regulatory path for its Fabry disease program and the submission of an IND application for a chronic neuropathic pain treatment.

• Announced clear regulatory pathway to Accelerated Approval from FDA for isaralgagene civaparvovec in Fabry disease.
• Pfizer to present detailed data from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec at ASH.

Seritage Growth Properties reported a net loss attributable to common shareholders of ($23.2) million, or ($0.41) per share, for the three months ended September 30, 2024. The company generated $24.0 million of gross proceeds from the sale of an income producing asset reflecting a 8.5% capitalization rate.

• Generated $24.0 million of gross proceeds from the sale of an income producing asset reflecting a 8.5% capitalization rate.
• Subsequent to September 30, 2024, generated $17.1 million in gross proceeds from a vacant/non-income producing asset sold at $87.43 PSF eliminating $0.6 million of carry costs.

ProKidney reported its Q3 2024 financial results, highlighting a successful FDA Type B meeting where the FDA confirmed the PROACT 1 Phase 3 study could support a full U.S. regulatory approval of rilparencel and that the accelerated approval pathway is available. The company ended the quarter with $406.8 million in cash and cash equivalents, supporting operations into 2027.

• FDA confirmed PROACT 1 Phase 3 study could be sufficient for full U.S. regulatory approval of rilparencel.
• FDA confirmed the availability of an accelerated approval pathway for rilparencel using a surrogate endpoint like eGFR slope.

BeautyHealth reported Q3 2024 net sales of $78.8 million, a decrease of 19.1% compared to Q3 2023. However, the company saw improved profitability with an increase in gross margin and adjusted EBITDA, driven by operational excellence initiatives and disciplined expense management. The company also revised its full year net sales guidance lower and improved its adjusted EBITDA guidance.

• Net sales were $78.8 million, a decrease of (19.1)% compared to Q3 2023, due to lower delivery systems net sales.
• Gross margin was 51.6% compared to (12.9)% in Q3 2023, primarily due to the absence of charges associated with the Syndeo Program in 2023 and lower inventory related charges.

FiscalNote reported Q3 2024 financial results, exceeding forecasts with total revenues of $29.4 million and adjusted EBITDA of $3.4 million. The company raised its full year 2024 adjusted EBITDA guidance and continues to focus on deleveraging its balance sheet and simplifying its product portfolio.

• Reported Q3 2024 total revenues of $29.4 million and adjusted EBITDA of $3.4 million, both exceeding previously provided forecast.
• Recorded fifth consecutive quarter of positive adjusted EBITDA.

Piedmont Lithium reported Q3 2024 financial results, highlighting record production at NAL and increased shipments. The company recognized revenue of $27.7 million from spodumene concentrate sales. Cost-saving measures and project advancements were also noted.

• NAL achieved record quarterly production of approximately 52,100 dmt.
• Piedmont shipped approximately 31,500 dmt of spodumene concentrate, generating $27.7 million in revenue.

Biote reported a 12.8% increase in third-quarter revenue, driven by procedure revenue growth and a strong return to growth in the dietary supplements business. The company saw a solid improvement in gross profit margin due to cost savings from vertical integration of manufacturing. Net income was $12.7 million, and adjusted EBITDA increased by 15.4% compared to the third quarter of 2023.

• Revenue increased to $51.4 million.
• Procedure revenue reached $37.9 million.

Evolution Petroleum Corporation reported a 6% increase in revenue to $21.9 million for the fiscal first quarter of 2025, driven by record oil production. Net income increased by 40% to $2.1 million, and adjusted EBITDA rose by 21% to $8.1 million. The company returned $4.0 million to shareholders in dividends and brought seven SCOOP/STACK wells online during the quarter.

• Fiscal Q1 revenues increased 6% year-over-year to $21.9 million, driven by record oil production.
• Net income for fiscal Q1 increased 40% year-over-year to $2.1 million.

eGain reported a 10% decrease in total revenue year-over-year, with revenue totaling $21.8 million. GAAP net income was $652,000, or $0.02 per share, while non-GAAP net income was $1.3 million, or $0.04 per share. The company highlighted a 16% year-over-year increase in annual recurring revenue for AI Knowledge Hub customers.

• Total revenue was $21.8 million, a 10% decrease year-over-year.
• GAAP net income was $652,000, or $0.02 per share.

SoundThinking reported a strong third quarter with a 10% increase in revenue to $26.3 million. Gross profit increased by 11%, and the company saw improvements in cash generation. The company reaffirms FY 2024 revenue guidance and introduces FY 2025 revenue guidance.

• Revenues increased 10% to $26.3 million compared to the same quarter in 2023.
• Gross profit increased 11% to $15.2 million (58% of revenues) compared to the same quarter in 2023.

RumbleOn reported a decrease in revenue for Q3 2024, but net losses reduced compared to the previous year. The company focused on reducing inventories and SG&A expenses, and secured additional capital from shareholders.

• Revenue decreased by 12.7% to $295.0 million.
• Net loss improved to $11.2 million from $16.5 million year-over-year.

Inseego Corp. reported Q3 2024 financial results with revenue of $61.9 million, positive Adjusted EBITDA of $9.3 million, and GAAP Net Income of $9.0 million. The company agreed to sell its telematics business for $52.0 million in cash and executed a convertible debt restructuring.

• Q3 2024 revenue from continuing and discontinued operations was $61.9 million.
• Positive Adjusted EBITDA from continuing and discontinued operations was $9.3 million.

PublicSquare reported a 222% increase in net revenue year-over-year and a gross margin of 64% for the third quarter of 2024. The company is prioritizing its Fintech opportunity, having signed contracts for over $1.0 billion in potential annualized gross merchandise value for payments.

• Net revenue increased by 222% year-over-year.
• Gross margin reached 64%.

Fate Therapeutics reported $3.1 million in revenue for the third quarter of 2024, primarily from preclinical development activities under its collaboration with Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $330.5 million as of September 30, 2024, which is projected to provide an operating runway through the end of 2026.

• Initial clinical data from Phase 1 autoimmunity study of FT819 1XX CAR T-cell product candidate to be presented in 4Q24.
• Second treatment arm adding FT819 to maintenance therapy without conditioning chemotherapy opened for enrollment.

RAPT Therapeutics reported a net loss of $18.4 million for the third quarter of 2024, compared to a net loss of $31.4 million for the same period in 2023. Research and development expenses decreased due to lower development costs, while general and administrative expenses also saw a decrease. A workforce reduction was implemented to conserve cash resources.

• Net loss for Q3 2024 was $18.4 million, a decrease from $31.4 million in Q3 2023.
• Research and development expenses decreased to $13.3 million, compared to $27.0 million in the same period in 2023.

Motorcar Parts of America reported a 5.9 percent increase in net sales, reaching a record $208.2 million for the fiscal second quarter of 2025. Gross profit also reached a record $41.3 million, and the company generated $22.9 million in cash from operating activities while reducing net bank debt by $22.0 million.

• Net sales increased 5.9 percent to a record $208.2 million.
• Gross profit increased to a record $41.3 million, impacted by certain one-time expenses of $2.7 million for onboarding new business, and $1.3 million of transition expenses.

TScan Therapeutics reported third quarter 2024 financial results, with revenue at $1.0 million compared to $3.9 million for the same period in 2023. Net loss was $29.9 million, compared to $23.0 million for the third quarter of 2023. Cash, cash equivalents, and marketable securities totaled $271.1 million, expected to fund operations into the fourth quarter of 2026.

• Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
• Company to host virtual KOL event on December 10th to discuss clinical updates from the ALLOHA Phase 1 trial and heme development strategy.

Veritone reported Q3 2024 revenue of $22.0 million, a 21% decrease compared to Q3 2023. The company completed the divestiture of its media agency in October 2024, focusing on becoming a pure-play enterprise AI company. They announced fiscal 2025 business outlook with up to 30% year over year forecasted revenue growth and over 45% forecasted improvement in Non-GAAP Net Loss as compared to fiscal 2024 guidance led by over $100 million in sales pipeline at Q3 2024

• Revenue was $22.0 million, down 21% year-over-year.
• Software Products and Services revenues were $14.7 million, a decrease of 28% compared to Q3 2023.

Babcock & Wilcox reported Q3 2024 results with revenue of $209.9 million and a net loss of $11.1 million. The company highlighted improved margin performance and progress on strategic sales and debt refinancing. Adjusted EBITDA was $22.3 million.

• Announced divestiture of two assets to improve balance sheet and support future growth
• Total YTD implied bookings of $810.5 million, including $543.9 million of bookings, a 27% increase compared to same period of 2023

Aemetis reported revenues of $81.4 million for Q3 2024, a 19% increase compared to Q3 2023. The company experienced revenue growth across all three operating segments: California Ethanol, India Biodiesel, and Dairy Renewable Natural Gas.

• Revenues for Q3 2024 were $81.4 million, up from $68.7 million in Q3 2023.
• California Ethanol business generated $45.0 million in revenues.

Milestone Pharmaceuticals is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT and is encouraged by clinician interest in the etripamil Phase 3 study in AFib-RVR.

• NDA for CARDAMYST™ in PSVT under review by FDA with a PDUFA date of March 27, 2025.
• Primary focus is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for PSVT management.

Synchronoss Technologies reported strong third quarter 2024 results, with revenue increasing by 8% year-over-year to $43.0 million, driven by subscriber growth and a high percentage of recurring revenue. The company also improved its profitability and signed a three-year extension with SFR.

• Total revenue increased to $43.0 million, primarily driven by 5.1% subscriber growth year-over-year.
• Recurring revenue accounted for 92.2% of total revenue.

Acumen Pharmaceuticals reported a net loss of $29.8 million for the third quarter of 2024. As of September 30, 2024, cash, cash equivalents and marketable securities totaled $258.9 million, which is expected to support current clinical and operational activities into the first half of 2027.

• ALTITUDE-AD Phase 2 study enrollment expected to complete in the first half of 2025.
• Topline results of Phase 1 study for subcutaneous administration of sabirnetug expected in the first quarter of 2025.

908 Devices reported a 17% increase in revenue compared to the prior year, driven by newly acquired handheld products. However, Q3 results fell short of expectations due to a delayed federal budget, international contract delays, and softness in the bioprocessing and life science instrumentation market. The company is implementing structural changes to increase cost efficiency and expand gross margins.

• Revenue increased by 17% year-over-year, driven by recently acquired handheld products.
• The installed base grew 20% year-over-year to 3,253 devices.

Agenus reported revenue of $25.1 million and a net loss of $67.2 million for Q3 2024. The company is focused on advancing BOT/BAL, strategic initiatives including asset monetization and operational efficiencies to strengthen its financial position.

• Botensilimab (BOT) and balstilimab (BAL) continues to deliver unprecedented outcomes across multiple cancer settings.
• BOT/BAL is advancing in 3 ISTs with consistent clinical activity in MSS CRC, a tumor historically resistant to immunotherapy.

Journey Medical reported solid third quarter 2024 results with total revenues of $14.6 million and highlighted the FDA approval of Emrosi™ for the treatment of inflammatory lesions of rosacea in adults, with launch expected in late Q1 or early Q2 of 2025.

• U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults.
• The launch of Emrosi is expected in late Q1 or early Q2 of 2025.

Rockwell Medical reported a strong third quarter in 2024, marked by increased net product sales, significant growth in gross profit, and a return to profitability. The company's net sales reached $28.3 million, driven by a large order of premium-priced products, and it generated $4.3 million in cash flow from operations.

• Net product sales increased by 31% compared to the same period in 2023, reaching $28.3 million.
• Gross profit increased by 183% compared to the same period in 2023, totaling $6.2 million.

Urban One, Inc. reported a decrease in net revenues for the quarter ended September 30, 2024, with an operating loss. The company saw declines in broadcast and digital operating income and net loss, but also experienced a strong uptick in political revenues beginning in September.

• Net revenues decreased by 6.3% compared to the same period in 2023.
• The Company reported an operating loss of approximately $26.2 million.

Atara Biotherapeutics reported Q3 2024 financial results, including total revenues of $40.2 million and a net loss of $21.9 million, with cash, cash equivalents, and short-term investments totaling $67.2 million as of September 30, 2024. The company's cash runway is expected to extend into 2027, supported by anticipated milestones, inventory purchases, and operating efficiencies.

• Tab-cel BLA is on track with PDUFA target action date of January 15, 2025.
• First patient dosed for ATA3219 Non-Hodgkin’s Lymphoma study; initial clinical data expected Q1 2025.

Tempest Therapeutics reported a net loss of $10.6 million for the third quarter of 2024. The company ended the quarter with $22.1 million in cash and cash equivalents. They also received a 'Study May Proceed' letter from the FDA for their pivotal Phase 3 trial of amezalpat combination therapy.

• Received FDA 'Study May Proceed' letter for pivotal Phase 3 trial of amezalpat combination therapy to treat first-line HCC.
• Announced agreement with Roche to support advancement of amezalpat into first-line HCC pivotal Phase 3 trial.

KALA BIO reported a net loss of $9.0 million, or $1.93 per share, for the third quarter ended September 30, 2024. The company had cash and cash equivalents of $49.2 million as of September 30, 2024.

• KALA is enrolling patients in the Phase 2b CHASE trial for PCED treatment, with topline data expected in Q2 2025.
• The company initiated five clinical trial sites in Argentina for the CHASE trial and is planning additional sites in Latin America.

Opus Genetics reported a net loss of $7.5 million for the quarter ended September 30, 2024, or $(0.29) per basic and diluted share, compared to a net income of $5.6 million for the third quarter of 2023. The company's cash and cash equivalents were approximately $37 million as of September 30, 2024, expected to fund operations into 2026.

• Ocuphire acquired Opus Genetics in October 2024, creating a gene therapy company focused on inherited retinal diseases (IRDs).
• The combined company's pro forma cash balance was approximately $37 million as of September 30, 2024, expected to extend runway into 2026.

GEN Restaurant Group reported a 7.8% increase in total revenue to $49.1 million for the third quarter of 2024. However, net income decreased to $0.2 million, or $0.01 per diluted share, due to higher expenses related to new restaurant openings. The company maintained a restaurant-level adjusted EBITDA margin above 18%.

• Opened one new location during the third quarter and two more locations in October 2024.
• Launched GEN Korean BBQ gift cards at participating Costco locations.

P3 Health Partners reported a 26% year-over-year increase in revenue to $362.1 million. However, the quarter was impacted by lower risk adjustments, higher medical expenses, and retroactive adjustments, leading to a net loss of $102.9 million and the withdrawal of the company's previous fiscal year guidance.

• Total revenue increased by 26% year-over-year, reaching $362.1 million.
• Capitated revenue grew by 25% year-over-year, totaling $357.7 million.

XBP Europe Holdings reported a revenue of $35.4 million, a decrease of 5.6% year-over-year. However, the company saw an increase in gross margin to 32.6% and an operating profit of $2.5 million. The net loss was $2.8 million, including $0.7 million of FX losses.

• Revenue was $35.4 million, a 5.6% decrease year-over-year but a 5.5% increase sequentially.
• Gross margin increased to 32.6%, an 800 bps increase year-over-year.

iBio reported no revenue for the first quarter ended September 30, 2024. The net loss from continuing operations was approximately $4.0 million, or $0.46 per share. Cash, cash equivalents and restricted cash totaled approximately $11.3 million.

• Advanced myostatin program with dosing underway in non-human primate study.
• Collaboration with AstralBio progressed, manufacturing and dosing a lead molecule.

CervoMed reported a net loss of $4.8 million for the third quarter of 2024, compared to a net income of $2.2 million for the same period in 2023. As of September 30, 2024, CervoMed had approximately $46.7 million in cash, cash equivalents and marketable securities.

• Completed final patient visits in RewindD-LB Phase 2b trial evaluating neflamapimod in patients with early-stage DLB and began preparing for database lock.
• Topline data from the RewindD-LB study is expected in December 2024.

Energous Wireless Power Solutions reported their Q3 2024 financial results, highlighting sales momentum and increased interest in their Wireless Power Network (WPN) technology, as they focus on commercial accounts, demonstrating the value of their solutions, and optimizing operations.

• Focused on gaining traction with significant commercial accounts.
• Demonstrated the value of wireless power network solutions to businesses.

TherapeuticsMD, a pharmaceutical royalty company, reported its financial results for the third quarter ended September 30, 2024. The company is primarily collecting royalties from its licensees.

• TherapeuticsMD reported financial results for Q3 2024.
• The company is a pharmaceutical royalty company.

Lyra Therapeutics reported its Q3 2024 financial results, highlighting the anticipation of key milestones from the ongoing ENLIGHTEN Phase 3 trials and the topline safety data from the ENLIGHTEN 1 safety extension study. The company's cash, cash equivalents, and short-term investments were $51.6 million as of September 30, 2024, expected to fund operations into the first quarter of 2026.

• Topline safety results from ENLIGHTEN 1 Phase 3 extension study indicated no product-related serious adverse events.
• Enrollment in ENLIGHTEN 2 completed.

Vroom Inc. reported its Q3 2024 financial results, highlighting a net loss from continuing operations of $(37.7) million. The company reached an agreement to restructure $290 million of unsecured convertible notes into equity through a prepackaged Chapter 11 case. The company is focused on maximizing the value of its remaining assets and executing its Long-Term Strategic Plan.

• Cash and cash equivalents totaled $51.1 million as of September 30, 2024.
• Liquidity available to UACC under the warehouse credit facilities was $32.9 million.

Longeveron Inc. reported financial results for the quarter ended September 30, 2024, and provided a business update, highlighting the advancement of Lomecel-BTM for HLHS and mild Alzheimer’s disease.

• Advanced Lomecel-BTM development for Hypoplastic Left Heart Syndrome (HLHS) and mild Alzheimer’s disease.
• Achieved over 80% enrollment in the ELPIS II clinical trial for HLHS.

Direct Digital Holdings reported a challenging quarter with a revenue decrease of 85% compared to the same period last year, primarily due to a disinformation campaign that disrupted business with partners and clients. Despite these challenges, the company has taken steps to address the issues, innovate its business, and secure new financing to support growth initiatives.

• Revenue for Q3 2024 was $9.1 million, a decrease of 85% compared to Q3 2023.
• Sell-side advertising revenue decreased by 96% to $2.2 million due to a major customer pausing its connection.

LogicMark reported a 14% increase in revenue to $2.7 million for Q3 2024, driven by higher sales of Guardian Alert 911 Plus and Freedom Alert Mini PERS hardware. The gross profit increased by 13% to $1.8 million, with a gross margin of 67%. The net loss was $1.6 million, or $0.20 per share.

• Revenue increased by 14% compared to the same period last year.
• Gross margin remained steady at 67%.

22nd Century Group reported a decrease in net revenues to $5.9 million, a gross profit loss of $(0.6) million, an increase in operating loss to $3.4 million, and an increase in net loss to $3.6 million for the third quarter of 2024. The company remains focused on achieving EBITDA breakeven results in the first quarter of 2025 and is moving forward with plans to launch additional products, including VLN® SKUs within key customer brand families.

• Net revenues decreased to $5.9 million compared to $7.9 million in the previous quarter.
• Gross profit was $(0.6) million, a decrease from $0.6 million in the previous quarter.

Blackstone Secured Lending Fund reported strong Q3 2024 results, featuring its highest net investment income on a dollar basis and record net asset value per share. Credit performance remained strong with minimal non-accruals. The company received a full-notch credit rating upgrade from Moody’s to Baa2.

• Net investment income of $186 million, or $0.91 per share.
• Net income of $152 million, or $0.75 per share.